Advertisement

Advances in Contraception

, Volume 2, Issue 1, pp 65–69 | Cite as

Effect of oral contraceptives on serum apoprotein levels

  • K. Fotherby
Article

Abstract

The effect of oral contraceptives on serum lipoprotein concentrations, as assessed by their cholesterol content, is determined by the doses of estrogen and progestogen and the type of progestogen they contain. Assay of the apoprotein content, instead of cholesterol content, measures a different aspect of lipoprotein metabolism. Changes in serum concentrations of apoproteins A and B in women using oral contraceptives are similar to those obtained by measuring low density lipoprotein (LDL) and high density lipoprotein (HDL) cholesterol.

Keywords

Public Health Cholesterol Estrogen Serum Concentration High Density Lipoprotein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Résumé

L'effet des contraceptifs oraux sur les concentrations de sérum lipoprotéique, déterminé par la teneur en cholestérol, est fonction des doses d'oestrogènes et de progestogènes et du type de progestogènes qu'elles contiennent. L'évaluation chimique de la teneur apoprotéique, et non pas de la teneur en cholestérol, permet de mesurer un aspect différent du métabolisme lipoprotéique. Les changements de concentration du sérum d'apoprotéines A et B chez les femmes qui utilisent des contraceptifs oraux sont du même ordre que ceux obtenus par la mesure du cholestérol à faible densité en lipoprotéines et à forte densité en lipoprotéines.

Resumen

El efecto de los anticonceptivos orales en concentraciones de lipoproteínas séricas, evaluados por su contenido en colesterol, es determinado por las dosis de estrógeno y progestágeno y el tipo de progestágeno que contienen. El análisis del contenido de apropoteína, en vex del contenido de colesterol, mide diferentes aspectos del metabolismo de las lipoproteínas. Los cambios en las concentraciones séricas de apoproteínas A y B en mujeres usando anticonceptivos orales, son similares a aquellas obtenidas midiendo el LDL y el HDL-colesterol.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    MillerN. E. (1982). Coronary atherosclerosis and plasma lipoproteins.J. Cardiovasc. Pharmacol.,4, Suppl. 2, 190–195Google Scholar
  2. 2.
    MaciejkoJ. J., HolmesD. R., KottkeB. A., ZinsmeisterA. R., DinhD. M. and MaoS. J. T. (1983). Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease.N. Engl. J. Med.,309, 385–389PubMedGoogle Scholar
  3. 3.
    KukitaH., HamadaM., HiwadaK. and KokubuT. (1985). Clinical significance of measurements of serum apolipoprotein A-I, A-II and B.Atherosclerosis,55, 143–149PubMedGoogle Scholar
  4. 4.
    AlbersJ. J., WahlP. W., CabanaV. G., HazzardW. R. and HooverJ. J. (1976). Quantitation of apolipoprotein A-I of human plasma high density lipoprotein.Metabolism,25, 633–644PubMedGoogle Scholar
  5. 5.
    PhillipsN. R., HavelR. J. and KaneJ. P. (1982). Serum apolipoprotein A-I levels.Am. J. Epidemiol.,116, 302–313PubMedGoogle Scholar
  6. 6.
    FotherbyK. (1985). Oral contraceptives, lipids and cardiovascular disease.Contraception,31, 367–394PubMedGoogle Scholar

Copyright information

© MTP Press Ltd 1980

Authors and Affiliations

  • K. Fotherby
    • 1
  1. 1.Royal Postgraduate Medical SchoolHammersmith HospitalLondonUK

Personalised recommendations